Frequently Asked Questions About Acceleron Aktie

No, you cannot buy Acceleron stock today because the company no longer exists as a publicly traded entity. Merck completed its acquisition of Acceleron Pharma on November 15, 2021, paying $180 per share in an all-cash transaction. The stock was delisted from NASDAQ, and the ticker symbol XLRN is no longer active. All former Acceleron shareholders received cash payment for their shares at the time of the merger closing. If you're interested in the assets that were part of Acceleron, those now belong to Merck & Co., which trades under the ticker symbol MRK on the New York Stock Exchange. Merck continues to develop Sotatercept and other programs that were part of Acceleron's pipeline.

Acceleron shareholders received exactly $180.00 in cash for each share they owned when the merger closed on November 15, 2021. This represented the full acquisition price agreed upon when Merck announced the deal in September 2021. There were no stock options or earnouts—it was a straightforward cash purchase. For shareholders who participated in the IPO in 2013 at $18 per share, this represented a tenfold return on investment over approximately eight years. The total transaction value was approximately $11.5 billion. Shareholders did not need to take any action to receive payment; the cash was automatically deposited into their brokerage accounts in exchange for their shares once the merger completed.

Acceleron Pharma's main commercial product was Reblozyl (luspatercept-aamt), developed and marketed in partnership with Bristol Myers Squibb. Reblozyl was approved by the FDA in November 2019 for treating anemia in adult patients with beta-thalassemia who require regular red blood cell transfusions. In April 2020, it received a second approval for treating anemia in adults with very low- to intermediate-risk myelodysplastic syndromes who require red blood cell transfusions. However, the most valuable asset was actually Sotatercept, an investigational drug for pulmonary arterial hypertension that was still in Phase 3 trials at the time of acquisition. Sotatercept's potential as a disease-modifying therapy for PAH was the primary driver behind Merck's decision to acquire Acceleron at a premium valuation.

Merck acquired Acceleron primarily to gain full ownership of Sotatercept, a late-stage drug candidate for pulmonary arterial hypertension that showed exceptional promise in clinical trials. The Phase 2 PULSAR trial demonstrated a 34.6% reduction in pulmonary vascular resistance, a key measure of disease severity, which was significantly better than existing treatments. Pulmonary arterial hypertension is a serious condition affecting tens of thousands of patients in the United States alone, with a market potential estimated in the billions of dollars annually. Merck saw Sotatercept as a potential blockbuster drug that could address an area of significant unmet medical need while fitting strategically into their cardiovascular and pulmonary portfolio. The acquisition also brought Merck expertise in TGF-beta biology and a share of revenues from Reblozyl, though Sotatercept was clearly the crown jewel of the transaction.

When Merck acquired Acceleron, the pharmaceutical giant integrated Acceleron's operations into its existing structure. Merck retained many Acceleron employees, particularly those with specialized expertise in TGF-beta biology and the development of Sotatercept and other pipeline programs. The Cambridge, Massachusetts facility where Acceleron was headquartered became part of Merck's research network. However, as is typical with acquisitions, there was likely some redundancy in administrative and support functions that resulted in position eliminations. Merck publicly stated its intention to preserve the scientific talent and continue advancing the programs that made Acceleron valuable, particularly the Phase 3 STELLAR trial program for Sotatercept. The exact number of positions retained versus eliminated was not publicly disclosed, but maintaining continuity in drug development programs typically requires keeping key scientific and clinical personnel.

Acceleron stock significantly outperformed major biotech indexes during its time as a public company from 2013 to 2021. The stock generated a total return of approximately 900% from its IPO price of $18 to the final acquisition price of $180, representing a compound annual growth rate of roughly 31% over eight years. In comparison, the NASDAQ Biotechnology Index (NBI) returned approximately 120% during the same period, while the S&P 500 returned about 180%. Acceleron's outperformance was driven by successful clinical trials, FDA approvals, and ultimately the premium acquisition by Merck. However, the stock also experienced significant volatility typical of clinical-stage biotech companies, with drawdowns of 30-40% occurring after disappointing trial results or during broader market corrections in the biotech sector. The stock's best single-year performance was in 2020, when it gained approximately 141% following positive Sotatercept data.

Investing in Acceleron carried substantial risks typical of clinical-stage biopharmaceutical companies. The primary risk was clinical trial failure—if Sotatercept or other drug candidates failed to demonstrate safety and efficacy in trials, the stock price would have declined sharply. Regulatory risk was also significant; even successful trials don't guarantee FDA approval. Financial risk existed because Acceleron operated at a net loss, burning through cash reserves to fund expensive clinical trials, which could have necessitated dilutive financing rounds. Competition risk came from other companies developing PAH treatments, including United Therapeutics and Johnson & Johnson. Patent expiration and intellectual property challenges could have undermined the company's competitive position. Additionally, the partnership structure with Bristol Myers Squibb for Reblozyl meant Acceleron didn't capture 100% of that product's economics. These risks were substantial enough that the company could have failed entirely, resulting in total loss for shareholders, though the Merck acquisition ultimately provided a successful exit.